Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy	Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm	Recruiting	Phase 2	2026-09-17		NCT07341191

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
BeOne Medicines	76
Canadian Cancer Trials Group	73

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Arthur J.E. Child Comprehensive Cancer Centre	Calgary	Canada	45
BCCA - Vancouver	Vancouver	Canada	22
Cross Cancer Institute	Edmonton	Canada	146
University Health Network	Toronto	Canada	52